NVO stock jumps nearly 8% after FDA approves first-ever oral Wegovy pill, but Eli Lilly investors worry about what happens next

NVO stock soars after the FDA’s December 22 approval of Novo Nordisk’s Wegovy oral pill, marking a historic moment in weight-loss treatment. The first and only oral GLP-1 medication cleared for weight management promises to expand patient access in early January 2026. Wall Street celebrates what could reshape the obesity treatment market for years to come.

FDA Approves Novo Nordisk’s History-Making Pill Formulation

The U.S. Food and Drug Administration officially approved oral semaglutide 25mg on December 22, 2025. This represents the first and only oral GLP-1 receptor agonist approved for chronic weight management in adults. Prior to this decision, all approved GLP-1 medications required weekly or daily injections, creating a significant barrier for many patients seeking weight-loss treatment.

The approval caps months of regulatory review following Novo Nordisk’s May 2025 submission of the marketing application. The daily pill offers approximately 16.6% average weight loss based on the OASIS 4 trial, providing comparable efficacy to injection alternatives. Importantly, regulators also granted approval for cardiovascular benefits, reducing the risk of serious cardiac events in patients with obesity and existing heart disease.

Novo Nordisk plans to distribute the medication across U.S. pharmacies starting in early January 2026. This timing could position the Wegovy pill as a game-changer for the pharmaceutical giant and the obesity treatment sector overall.

Wall Street Responds with Immediate Stock Surge Following Announcement

NVO stock jumped approximately 8% during after-hours trading on December 22 following the FDA approval announcement. The stock closed regular trading at $48.10 before surging in the extended session. This reaction reflects investor optimism about the pill’s market potential and its ability to expand Novo Nordisk’s addressable patient population.

The stock movement comes after NVO shares declined significantly from all-time highs, down roughly 66% from a peak of $142 in June 2024. Market analysts maintain a consensus “Buy” rating with average price targets around $54.25, suggesting potential upside of roughly 12.8% from current levels. The oral approval could support a recovery narrative for investors who view Novo Nordisk as undervalued despite competitive pressures from Eli Lilly’s Mounjaro and Zepbound.

The Oral GLP-1 Market Opportunity: Expanding Access and Revenue Streams

Category	Details
Medication Core	Oral semaglutide 25mg once-daily pill formulation
OASIS 4 Results	16.6% average weight loss in clinical trials
U.S. Launch Timeline	Early January 2026
Cardiovascular Approval	Reduces serious cardiac events in obese patients with heart disease
Market Projection 2030	Analysts project $18.1 billion in Wegovy franchise revenue by 2030

The obesity GLP-1 market is experiencing explosive projected growth. Analysts forecast the sector could expand from $8.3 billion in 2025 to $65.4 billion by 2035, representing a compound annual growth rate of 23.1%. The GLP-1 receptor agonist market overall is estimated at $70 billion in 2025 and could reach $201.8 billion by 2033, growing at 12.8% annually.

The shift from injection-only options to an oral pill removes friction from patient adoption. Injection fatigue represents a documented challenge for long-term medication adherence. By offering a once-daily pill, Novo Nordisk captures patients who were hesitant about needles. Additionally, Medicare coverage discussions are underway for weight-loss medications starting in 2026, which could unlock demand from millions of seniors currently excluded from treatment access.

Competitive Dynamics: How Novo Nordisk Maintains Position Against Eli Lilly

Eli Lilly’s Mounjaro and Zepbound demonstrated superior weight-loss performance in head-to-head studies, producing up to 28.7% weight loss compared to Novo Nordisk’s offerings. This clinical advantage helped Eli Lilly capture significant market share and become the first pharma company to reach a $1 trillion market valuation. Analysts project Mounjaro could generate $36 billion in 2026 revenue while Novo Nordisk’s semaglutide franchise faces pricing pressures and competitive erosion.

The oral Wegovy pill represents Novo Nordisk’s strategic response to this competitive gap. Rather than competing on pure efficacy, Novo Nordisk emphasizes convenience and patient preference. Analysts project the oral formulation could generate substantially higher adoption rates among needle-averse patients. Furthermore, Novo Nordisk filed for CagriSema, a next-generation combination drug showing 20% weight loss in trials, potentially challenging Lilly’s dominance by 2027 or 2028.

What Happens Next: Investor Expectations and 2026 Catalysts for NVO Stock

The January 2026 launch of the Wegovy pill represents a major catalyst for NVO stock performance. Early prescribing patterns, patient adoption curves, and pharmacy stocking levels will signal whether the oral formulation can genuinely move market share. Investment firms will monitor first-quarter and second-quarter 2026 earnings closely for evidence of sustainable demand. Any surprise weakness in uptake could pressure stock valuations given current recovery expectations.

European regulatory applications are also in motion, with Novo Nordisk seeking approvals beyond the United States. Global expansion could significantly expand the addressable market. Additionally, higher-dose Wegovy injections earned Committee for Medicinal Products backing in December, signaling potential EU approval in 2026. Medicare coverage decisions expected later in 2026 could represent an enormous upside surprise if broader reimbursement expands demand exponentially.

Will This Oral Pill Be Enough to Restore Novo Nordisk’s Momentum?

The FDA approval is undeniably positive, but Novo Nordisk faces formidable headwinds. Eli Lilly’s clinical advantage, aggressive manufacturing scale, and pricing leverage position the competitor favorably. However, oral convenience could prove decisive for millions of patients. The coming months will reveal whether the Wegovy pill validates Novo Nordisk’s strategy or if Lilly’s superiority remains insurmountable in the therapy landscape.